The Company continues to progress discussions with its corporate...

The Company continues to progress discussions with its corporate advisor, Canaccord Genuity (Australia) Limited, with respect to the proposed Capital Raising, details of which will be announced to the market in due course. In the interim, the Company is being provided with a working capital loan of approximately $440,000 from its largest shareholder, Peters Investments Pty Ltd (an entity controlled by Bob Peters), which shall convert into equity at the prevailing price of the Capital Raising and is otherwise on arm’s length terms.

Peters has loaned $440K to see through this issue, taking up shares at the cap raise when all is fixed. Canaacord Genuity found the issue.

R&D refund to come soon also.

9 June 2022 announcement: Professor Aitken is now in the process of preparing a paper regarding the above to be peer reviewed and published in a substantive reproductive science journal.
https://www.asx.com.au/asxpdf/20220609/pdf/459s3k47bf4v1w.pdf

Product isn't a watch or a phone etc, perhaps consider the hurdles and regulations etc as a HUGE MOAT for the competition. All KOL reports in, Aitken is gathering data to write a paper, USA market boxes being ticked etc etc ..... the horse stuff on hold is smart as it's further away for sales than Felix & cartridges. Overcoming issues is more important than chucking a tanty and carrying on, the product is superior and there is a market, just need to be patient....... post covid the world has less risk appetite and a bit more bearish with pessimism but overall people go about their usual life and babies are part of that.